GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Pre-Tax Income

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Pre-Tax Income : $276 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Santen Pharmaceutical Co's pretax income for the three months ended in Dec. 2023 was $66 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $276 Mil. Santen Pharmaceutical Co's pretax margin was 12.31%.

During the past 13 years, Santen Pharmaceutical Co's highest Pretax Margin was 40.69%. The lowest was -2.08%. And the median was 16.28%.


Santen Pharmaceutical Co Pre-Tax Income Historical Data

The historical data trend for Santen Pharmaceutical Co's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Pre-Tax Income Chart

Santen Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 387.94 298.06 107.53 300.36 -43.39

Santen Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.66 43.35 91.03 75.80 65.87

Competitive Comparison of Santen Pharmaceutical Co's Pre-Tax Income

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Pre-Tax Income falls into.



Santen Pharmaceutical Co Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Santen Pharmaceutical Co's Pretax Income for the fiscal year that ended in Mar. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-23.118+0+-11.215+8.626+-17.678
=-43

Santen Pharmaceutical Co's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=76.802+0+-4.883+3.375+-9.424
=66

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $276 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santen Pharmaceutical Co  (OTCPK:SNPHY) Pre-Tax Income Explanation

Santen Pharmaceutical Co's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=65.87/534.978
=12.31%

During the past 13 years, Santen Pharmaceutical Co's highest Pretax Margin was 40.69%. The lowest was -2.08%. And the median was 16.28%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santen Pharmaceutical Co Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood 04-23-2020

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood 04-23-2020